Inspire Medical Systems, Inc.
INSP · NYSE
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.21 | -4.32 | 0.43 | 0.97 |
| FCF Yield | -0.16% | -0.32% | 1.13% | 0.70% |
| EV / EBITDA | 3,457.88 | 653.98 | 95.13 | 382.48 |
| Quality | ||||
| ROIC | -0.72% | -0.16% | 4.25% | 1.80% |
| Gross Margin | 84.03% | 84.75% | 84.99% | 84.06% |
| Cash Conversion Ratio | 6.90 | -0.75 | -2.24 | 1.96 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.68% | 17.86% | 21.68% | 25.32% |
| Free Cash Flow Growth | 58.22% | -124.31% | 40.38% | 455.03% |
| Safety | ||||
| Net Debt / EBITDA | -68.02 | -2.83 | -2.09 | -7.56 |
| Interest Coverage | -829.00 | 0.00 | 1,449.27 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.29 | 0.31 | 0.45 | 0.48 |
| Cash Conversion Cycle | 234.82 | 248.29 | 138.55 | 130.05 |